Ourself

Before they were trying to plump lips without a needle, the people behind this brand had already built two of the professional-grade skincare lines dermatologists keep in their dispensaries. Scott Glenn and Lauren Otsuki are the duo who founded SkinMedica, the growth-factor pioneer, and later Alastin Skincare, the post-procedure favorite of cosmetic practices, alongside a string of pharmaceutical ventures aimed at infertility, diabetes, cardiovascular disease, and cancer. That second career, building complex molecules that actually have to reach a target inside the body, is the real backstory here. Their thesis was that the limiting factor in topical skincare isn't the ingredient but the journey: most active molecules simply sit on the surface, too large or too fragile to travel anywhere useful. The proprietary answer became a portfolio of bio-engineered "intelligent peptides," or Intides, paired with a layered capsule system meant to ferry hyaluronic acid and peptides past the outermost barrier. Paired with marketer Vimla Black-Gupta, who took the president's seat, the founders framed the whole enterprise as clinical skincare's comeback after years of minimalist, feel-good branding dominating shelves. Venture capital agreed quickly: roughly thirty million dollars flowed in from investors including Lightspeed Venture Partners and First Round Capital, an unusually large early raise for a beauty newcomer and a sign that the technology story carried weight beyond the cosmetics press. The flagship lip product anchors a range extending into pigmentation, firming, and sun care, with prices that climb into procedure-adjacent territory. The honest tension is that pedigree and delivery science, however genuine, still can't make a swipe-on serum equal an injection. What the founders' track record does buy is credibility that the engineering is real, not the marketing flourish it might be from less proven hands.

Sources:[1][2][3][4]